Friday, Oct. 18, 2019 Diluted, Effective Ebola Vaccine Could Help Supplies Stretch Farther A single dose of a highly diluted VSV-Ebola virus vaccine—approximately one-millionth of what is in the vaccine being used to help control the ongoing Ebola outbreak in the Democratic Republic of the Congo—remains fully protective against disease in experimentally infected monkeys, according to NIAID scientists. The study appears in Lancet's EBioMedicine. Nearly 250,000 people have received the investigational vaccine since August 2018 as part of a "ring vaccination" program to help stem the DRC outbreak. The vaccine appears to be safe and highly effective, but the continued need to vaccinate people in the DRC and surrounding countries makes vaccine shortages a concern. Further dose reduction is a possible solution. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107